Abstract:The clinical application of chimeric antigen receptor (CAR) T‐cell therapy has rapidly changed the treatment options for terminally ill patients with defined blood‐borne cancer types. However, CAR T‐cell therapy can lead to severe therapy‐associated toxicities including CAR‐related hematotoxicity, ON‐target OFF‐tumor toxicity, cytokine release syndrome (CRS) or immune effector cell‐associated neurotoxicity syndrome (ICANS). Just as CAR T‐cell therapy has evolved regarding receptor design, gene transfer systems and production protocols, the management of side effects has also improved. However, because of measures taken to abrogate adverse events, CAR T‐cell viability and persistence might be impaired before complete remission can be achieved. This has fueled efforts for the development of extrinsic and intrinsic strategies for better control of CAR T‐cell activity. These approaches can mediate a reversible resting state or irreversible T‐cell elimination, depending on the route chosen. Control can be passive or active. By combination of CAR T‐cells with T‐cell inhibiting compounds, pharmacologic control, mostly independent of the CAR construct design used, can be achieved. Other strategies involve the genetic modification of T‐cells or further development of the CAR construct by integration of molecular ON/OFF switches such as suicide genes. Alternatively, CAR T‐cell activity can be regulated intracellularly through a self‐regulation function or extracellularly through titration of a CAR adaptor or of a priming small molecule. In this work, we review the current strategies and mechanisms to control activity of CAR T‐cells reversibly or irreversibly for preventing and for managing therapy‐associated toxicities.

Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review

Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Evolving strategies for addressing CAR T-cell toxicities

The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology

Tuning CAR T-cell therapies for efficacy and reduced toxicity

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Recent advances and discoveries in the mechanisms and functions of CAR T cells

Small molecule-regulated switches to provide functional control of CAR T cells within the patient

Current understanding and management of CAR T cell-associated toxicities

Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics

CAR T-cell immunotherapy: The path from the by-road to the freeway?

CAR-T cell therapy: current limitations and potential strategies

Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Enhancing the Safety of CAR-T Cell Therapy: Synthetic Genetic Switch for Spatiotemporal Control.

Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review

Research Advances in Chimeric Antigen Receptor-Modified T-cell Therapy (Review)

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity